Elliott portfolio manager behind GSK and Freseni campaigns leaves firm
The Elliott Management investor behind activist campaigns at UK healthcare giant GSK and Germany’s Fresenius has left the £55.7bn hedge fund, adding to an exodus of senior figures in its London office.
Sebastien de La Riviere, who had worked in Elliott’s London office since 2008, left in recent weeks and his positions in GSK and Fresenius, the world’s largest dialysis company, have been reallocated to other portfolio managers inside the firm, said people familiar with the matter.
It is the latest high-profile departure inside Elliott’s London office, where several key figures left the firm last year. Among them was senior portfolio manager Mark Levine, a longstanding and close ally of Gordon Singer, the son of Elliott’s founder Paul Singer who leads the London office.
The hedge fund also urged the GSK board to evaluate takeover offers for the joint venture with Pfizer that was later spun-off as Haleon. GSK later rejected a £50bn bid from Unilever to acquire the unit and there were no other offers.
This story originally appeared on: Financial Times - Author:Ortenca Aliaj
